title: Cannabinoids control spasticity and tremor in a multiple sclerosis model.
abstract: Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune model of multiple sclerosis. Although both these diseases are typified by relapsing-remitting paralytic episodes, after CREAE induction by sensitization to myelin antigens Biozzi ABH mice also develop spasticity and tremor. These symptoms also occur during multiple sclerosis and are difficult to control. This has prompted some patients to find alternative medicines, and to perceive benefit from cannabis use. Although this benefit has been backed up by small clinical studies, mainly with non-quantifiable outcomes, the value of cannabis use in multiple sclerosis remains anecdotal. Here we show that cannabinoid (CB) receptor agonism using R(+)-WIN 55,212, delta9-tetrahydrocannabinol, methanandamide and JWH-133 (ref. 8) quantitatively ameliorated both tremor and spasticity in diseased mice. The exacerbation of these signs after antagonism of the CB1 and CB2 receptors, notably the CB1 receptor, using SR141716A and SR144528 (ref. 8) indicate that the endogenous cannabinoid system may be tonically active in the control of tremor and spasticity. This provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis, and provides a means of evaluating more selective cannabinoids in the future.
authors.affiliation: Department of Neurochemistry, Institute of Neurology, University College London, UK. D.Baker@ion.ucl.ac.uk
authors.forename: D
authors.initials: D
authors.lastname: Baker
authors.forename: G
authors.initials: G
authors.lastname: Pryce
authors.forename: J L
authors.initials: JL
authors.lastname: Croxford
authors.forename: P
authors.initials: P
authors.lastname: Brown
authors.forename: R G
authors.initials: RG
authors.lastname: Pertwee
authors.forename: J W
authors.initials: JW
authors.lastname: Huffman
authors.forename: L
authors.initials: L
authors.lastname: Layward
mesh_terms: D000818:Animals; D001892:Camphanes / Q000494:pharmacology; D002186:Cannabinoids / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D013035:Spasm / Q000188:drug therapy*; D014202:Tremor / Q000188:drug therapy*
chemical_list: D001892:Camphanes; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C110630:SR 144528; D000077285:Rimonabant